Evidence map›Paper›PMID 32840996›Full record

ArticleACS chemical neuroscience2020

Neuroprotective and Anti-neuroinflammatory Properties of Ebselen Derivatives and Their Potential to Inhibit Neurodegeneration.

Alexander D Landgraf, Amsha Saud Alsegiani, Saleh Alaqel, Sandeep Thanna, Zahoor A Shah, Steven J Sucheck

Open access · greenAbstract read
In one paragraph

Article in ACS chemical neuroscience, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 1 pooled it
4.9field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 1 synthesis or guideline pooled it, 51 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Navigating the redox landscape: reactive oxygen species in regulation of cell cycle.Redox report : communications in free radical research · 2024
    Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Alexander D LandgrafDepartment of Chemistry and Biochemistry, University of Toledo, 2801 West Bancroft Street, Toledo, Ohio 43606, United States.
Amsha Saud AlsegianiDepartment of Medicinal and Biological Chemistry, University of Toledo Health Science Campus, 3000 Arlington Avenue, Toledo, Ohio 43614, United States.
Saleh AlaqelDepartment of Medicinal and Biological Chemistry, University of Toledo Health Science Campus, 3000 Arlington Avenue, Toledo, Ohio 43614, United States.
Sandeep ThannaFox Chase Chemical Diversity Center, Inc., Pennsylvania Biotechnology Center, 3805 Old Easton Road, Doylestown, Pennsylvania 18902, United States.ORCID 0000-0003-4883-981X
Zahoor A ShahDepartment of Medicinal and Biological Chemistry, University of Toledo Health Science Campus, 3000 Arlington Avenue, Toledo, Ohio 43614, United States.ORCID 0000-0001-8977-1618
Steven J SucheckDepartment of Chemistry and Biochemistry, University of Toledo, 2801 West Bancroft Street, Toledo, Ohio 43606, United States.ORCID 0000-0003-0082-3827
University of Toledo · USFox Chase Chemical Diversity Center · US

Funding

Understanding trehalose synthesis and utilization in mycobacteriaR01AI105084 · NIAID · UNIVERSITY OF TOLEDO · PI RONNING, DONALD R, SUCHECK, STEVEN · 2013 to 2022
$3.7M
Methods to synthesize oligosaccharide-fusion protein conjugates and enhancement of their antigenicityR01AI148570 · NIAID · UNIVERSITY OF TOLEDO · PI SUCHECK, STEVEN, WALL, KATHERINE A · 2020 to 2024
$2.3M
Synthesis of natural product scaffold selectively active against dormant Mycobacterium tuberculosisR21AI135313 · NIAID · UNIVERSITY OF TOLEDO · PI ROHDE, KYLE H, SUCHECK, STEVEN · 2018 to 2019
$423k
NIAID NIH HHS R01 AI105084NIAID NIH HHS R01 AI148570NIAID NIH HHS R21 AI135313
6 · The paper itself

Abstract

Ebselen (EBS) is an organo-selenium-containing compound that has anti-inflammatory, antitumor, and antibacterial properties. EBS is being explored as a possible treatment for reperfusion injury and stroke and is under clinical trials as a mimetic of lithium for the treatment of bipolar disorder [Mota et al.

Indexed as

Neuroprotective AgentsOrganoselenium CompoundsAzolesHumansIsoindolesNeuroprotectionAzolesebselenIsoindolesNeuroprotective AgentsOrganoselenium CompoundsAlzheimer’s diseaseAnti-neuroinflammatoryEbselenNeurodegenerationNeuroprotective

Identifiers

PMID32840996
PMCPMC8628187
OpenAlexW3080074305

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.